Lijun Cai

Mr. Lijun Cai

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2023 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
LCLijun Cai
Lijun Cai
LCLiyile Chen
Liyile Chen
CZChengcheng Zhao
Chengcheng Zhao
QWQiuru Wang
Qiuru Wang
PKPengde Kang
Pengde Kang
Background: Total hip arthroplasty (THA) is an excellent treatment for the end-stage hip disease, and perioperative blood management strategies have been effectively applied to this procedure. However, many patients still experience anemia after the operation, which is usually overlooked by orthopedic surgeons due to the hidden blood loss (HBL) in the perioperative period. Therefore, the objective of this study was to evaluate HBL in patients undergoing primary THA using the posterior approach and to explore its influencing factors. Methods: A retrospective analysis of 707 patients who underwent primary THA through the posterior approach was conducted in our hospital from January 2020 to January 2022. By applying Gross’s and Nadler’s formula, the HBL was calculated. Six quantitative variables (age, body mass index, surgical duration, albumin loss, preoperative hemoglobin, and hemoglobin loss) as well as four qualitative variables (gender, American Society of Anesthesiologists class, major preoperative diagnosis, and hypertension) of patients were analyzed using multivariate linear regression. Results: The HBL was recorded at 700.39 ± 368.59 mL. As a result of multivariate linear regression analysis, it was determined that body mass index, surgical duration, and hemoglobin loss were all significant risk factors for HBL, whereas preoperative hemoglobin was considered a protective factor. It has been demonstrated that HBL is not significantly correlated with age, albumin loss, gender, ASA class, or major preoperative diagnosis, but it also did not differ from HBL by hypertension. Conclusions: Hidden blood Loss (HBL) in patients after primary total hip arthroplasty (THA) using the posterior approach is large and significant. When optimizing the perioperative management of THA, orthopedic surgeons should keep in mind HBL and its influencing factors, especially for patients with high body mass indexes, long surgical durations, and low preoperative hemoglobin levels. Trial registration: This study was registered in the Chinese Clinical Trial Registry (ChiCTR2100053888) in 02/12/2021, http://www.chictr.org.cn.

18 December 2023 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
QWQiuru Wang
Qiuru Wang
QJQunhua Jin
Qunhua Jin
LCLijun Cai
Lijun Cai
CZChengcheng Zhao
Chengcheng Zhao
PFPengfei Feng
Pengfei Feng
PKPengde Kang
Pengde Kang
Background: Many patients experience lower-extremity swelling following total knee arthroplasty (TKA), which impedes recovery. Diosmin is a semisynthetic flavonoid that is often utilized to treat swelling and pain caused by chronic venous insufficiency. We aimed to evaluate the efficacy and safety of diosmin in reducing lower-extremity swelling and pain as well as in improving functional outcomes following TKA. Methods: This study was designed as a randomized, controlled multicenter trial and conducted in 13 university-affiliated tertiary hospitals. A total of 330 patients undergoing TKA were randomized to either receive or not receive diosmin postoperatively. The diosmin group received 0.9 g of diosmin twice per day for 14 consecutive days starting on the day after surgery, whereas the control group received neither diosmin nor a placebo postoperatively. The primary outcome was lower-extremity swelling 1, 2, 3, and 14 days postoperatively. The secondary outcomes were postoperative pain assessed with use of a visual analogue scale, Hospital for Special Surgery score, range of knee motion, levels of the inflammatory biomarkers C-reactive protein and interleukin-6, and complications. Results: At all postoperative time points, diosmin was associated with significantly less swelling of the calf, thigh, and upper pole of the patella as well as with significantly lower pain scores during motion. However, no significant differences in postoperative pain scores at rest, Hospital for Special Surgery scores, range of motion, levels of inflammatory biomarkers, or complication rates were found between the diosmin and control groups. Conclusions: The use of diosmin after TKA reduced lower-extremity swelling and pain during motion and was not associated with an increased incidence of short-term complications involving the outcomes studied. However, further studies are needed to continue exploring the efficacy and safety of diosmin use in TKA. Level of Evidence: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.

23 October 2023 in Asian Journal of Surgery
Verified
Journal Article
Open access
LCLijun Cai
Lijun Cai
CCChangjun Chen
Changjun Chen
PKPengde Kang
Pengde Kang
PKPengde Kang
Pengde Kang

8 October 2026 in Orthopaedic Surgery
Verified
Journal Article
Open access
BLBohua Li
Bohua Li
MZManxue Zhang
Manxue Zhang
QLQianhao Li
Qianhao Li
LCLijun Cai
Lijun Cai
LCLiyile Chen
Liyile Chen
PKPengde Kang
Pengde Kang
Objective: The impact of psychological factors on surgical stress response has garnered extensive attention. However, perioperative intervention strategies are still lacking for the total hip arthroplasty (THA) population without psychiatric comorbidities. This study aimed to assess the efficacy of duloxetine in perioperative anxiety status and stress response in these patients. Methods: This was a double‐blind randomized controlled trial conducted between September 2021 and August 2024. Eligible patients aged over 18 years scheduled for unilateral primary total hip arthroplasty were recruited, with exclusion of patients with diagnosed mental diseases, endocrine disorders, previous psychiatric medication use, or severe hepatorenal dysfunction. A computer‐generated random sequence was used to assign 100 patients to either the duloxetine group or the placebo group. The patients received 60 mg of duloxetine or the placebo daily starting 2 days before the surgery to postoperative day two. The primary outcome was the anxiety status assessed using the Hamilton anxiety scale (HAMA). The self‐rating anxiety scale (SAS), stress response‐related inflammatory levels and neuroendocrine levels, visual analog scale (VAS), patient satisfaction, quality of recovery‐15 (QoR‐15) score, Harris hip score (HHS), University of California Los Angeles (UCLA) activity score, and adverse effects were also compared. Continuous outcomes with multiple time points were analyzed using linear mixed models, while single time point outcomes used t ‐test or Mann–Whitney U test. Preoperative to POD1 differences were assessed with paired t ‐test or Wilcoxon test. Categorical variables and response rate were analyzed using chi‐square or Fisher's exact test. Correlation analysis examined anxiety and stress biomarker relationships. Statistical significance was set at p < 0.05. Results: The duloxetine group had significantly lower HAMA and SAS scores than the placebo group on POD2 (both p < 0.05). The VAS score during walking was significantly lower in the duloxetine group ( p < 0.05). Patients in the duloxetine group exhibited higher QoR‐15, HHS, and UCLA scores and better satisfaction (all p < 0.05). The erythrocyte sedimentation rate (ESR), neutrophil/lymphocyte ratio (NLR), tumor necrosis factor alpha (TNF‐α), adrenocorticotropic hormone (ACTH), plasma cortisol (PTC), and blood glucose (BG) were significantly lower in the duloxetine group (all p < 0.05). The ESR and HAMA, ACTH and SAS, and PTC and SAS were respectively correlated (all p < 0.05). Conclusion: The perioperative administration of duloxetine alleviated anxiety, reduced postoperative walking pain, improved the quality of functional recovery and satisfaction, and may reduce the stress response in patients undergoing THA. Trial Registration: Clinical Trial Register: ChiCTR2100051099.